Framingham, MA, United States of America

Paul S Charifson

USPTO Granted Patents = 65 

 

 

Average Co-Inventor Count = 9.0

ph-index = 17

Forward Citations = 648(Granted Patents)

Forward Citations (Not Self Cited) = 388(Oct 12, 2025)


Inventors with similar research interests:


Location History:

  • Framington, MA (US) (2012 - 2016)
  • Farmingham, MA (US) (2016)
  • Framingham, MA (US) (2002 - 2024)

Company Filing History:


Years Active: 2002-2025

Loading Chart...
Loading Chart...
Loading Chart...
65 patents (USPTO):

Title: Innovator Spotlight: Paul S Charifson - Pioneering DNA-PK Inhibitors

Introduction:

Paul S Charifson, a renowned inventor based in Framingham, MA, has made significant contributions to the field of molecular biology with his groundbreaking work on DNA-PK inhibitors. With an impressive portfolio of 64 patents to his name, Charifson's innovative approach has paved the way for new avenues in pharmaceutical research and development.

Latest Patents:

Charifson's latest patents revolve around DNA-PK inhibitors, compounds that hold immense potential in the treatment of various diseases, conditions, or disorders. These compounds not only serve as inhibitors of DNA-PK but also form the basis of pharmaceutically acceptable compositions that can be utilized in the development of novel therapeutic interventions.

Career Highlights:

Throughout his career, Paul S Charifson has been associated with leading companies in the pharmaceutical industry, including Vertex Pharmaceuticals, Inc. and Spero Trinem, Inc. His expertise and novel inventions have played a pivotal role in shaping the landscape of the biotech sector, earning him accolades and recognition from peers and professionals alike.

Collaborations:

Charifson has collaborated closely with esteemed professionals such as Hongbo Deng and Emanuele Perola, pooling their collective knowledge and experience to drive innovation and scientific progress in the realm of molecular biology and drug discovery. These collaborations have been instrumental in bringing forth cutting-edge technologies and therapeutics to the forefront of medical research.

Conclusion:

In conclusion, Paul S Charifson stands as a stalwart figure in the realm of innovation and invention, with his groundbreaking work on DNA-PK inhibitors demonstrating his unwavering commitment to advancing scientific knowledge and improving healthcare outcomes. His contributions have not only revolutionized the field of molecular biology but have also set new standards for excellence and ingenuity in the realm of pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…